Synergistic Approach of Antibody‐Photosensitizer Conjugate Independent of KRAS‐Mutation and Its Downstream Blockade Pathway in Colorectal Cancer

Abstract

Here, we present a novel approach to improve the efficacy of antibody‐drug conjugates (ADC) by integrating antibody‐mediated immunotherapy and photodynamic therapy (PDT) in a combination therapy system utilizing an antibody‐photosensitizer conjugate (APC) platform based on a poloxamer polymer linker. To specifically target KRAS‐mutated cancer cells, we synthesized an antibody anti‐epidermal growth factor receptor (EGFR), cetuximab, with a poloxamer linker coupled with the photosensitizer chlorin e6 (MPXC) through click chemistry (CMPXC). CMPXC was cytotoxic upon laser treatment, achieving a 90% cell death by suppressing KRAS downstream signaling pathways associated with ERK and AKT proteins, confirmed using RNA sequencing analysis. In KRAS‐mutated colorectal cancer (CRC) mouse models, CMPXC significantly enhanced antitumor efficacy compared with cetuximab treatment alone, resulting in an 86% reduction in tumor growth. Furthermore, CMPXC treatment led to a 2.24‐ and 1.75‐fold increase in dendritic and priming cytotoxic T cells, respectively, highlighting the immune‐activating potential of this approach. Our findings suggest that the APC platform addresses the challenges associated with ADC development and EGFR‐targeted therapy, including the synergistic advantages of antibody‐mediated immunotherapy and PDT.This article is protected by copyright. All rights reserved

Supramolecular 3 in 1: A Lubrication and Co-Delivery System for Synergistic Advanced Osteoarthritis Therapy

“…Over the past several decades, clinical practice and exploratory studies have demonstrated that a singular treatment modality is ineffective in combating refractory diseases, such as cancer, diabetes, arthritis, and multiple sclerosis, due to its complexity, heterogeneity, and drug resistance. − In line with therapeutic advancements, combination therapies have emerged as a superior approach to overcome monotherapy limitations. ,− Combination therapy, achieved by concurrently administering multiple drugs or integrating diverse therapeutic modalities, can enhance therapeutic effectiveness, minimize side effects, combat drug resistance, and mitigate the chances of recurrence. ,, For example, the highly active antiretroviral therapy, which involves the combination of three or more anti-HIV drugs, has become the predominant therapeutic approach for acquired immune deficiency syndrome. , Moreover, the World Health Organization recommends artemisinin combination therapy as the primary treatment for malaria patients . Significantly, the growing acknowledgment of the distinct benefits of combination therapy over monotherapy in treating various diseases has fostered its gradual adoption in clinical settings.…”

Reversing cancer immunoediting phases with a tumor-activated and optically reinforced immunoscaffold

“…The intrinsic scarcity of tumor antigens led to poor tumor recognition and cytotoxicity of T cells. Recently, radiotherapy [ 18 , 19 ], chemotherapy [ 20 , 21 ], and phototherapy [ [22] , [23] , [24] , [25] ] have been reported to promote tumor antigen exposure in TME, thus improving the immunogenicity of ISV. Among them, photothermal therapy (PTT) has emerged as a novel ISV paradigm due to its high selectivity, low systemic toxicity, and limited therapeutic resistance [ [26] , [27] , [28] , [29] ].…”